Background Colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.Novel drugs for CRC therapy are urgently needed.Digoxin has been in clinical use for treatment of heart failure and atrial arrhyt...Background Colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.Novel drugs for CRC therapy are urgently needed.Digoxin has been in clinical use for treatment of heart failure and atrial arrhythmias for many years.Fragmentary reports suggested that digoxin might have antitumor efficacy on CRC.Here,we aimed to investigate the antitumor effect of digoxin on human CRC cells and the underlying mechanism.Methods Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay and plate colony formation assay.The effects of digoxin on cell-cycle distribution and apoptosis were analysed by flow cytometry.The anti-metastatic effect on tumor cells was determined by wound-healing assay and transwell assay.Anti-angiogenic effect was examined by determining the inhibition against proliferation,migration,and tube formation of human umbilical vein endothelial cells(HUVECs).Mechanism study was performed by Western blot,enzyme-linked immunosorbent assay(ELISA),and gelatin-zymography assay.Results Digoxin potently inhibited cell proliferation,induced G1-phase and G2/M-phase arrest in colorectal-cancer HCT8 and SW620 cells,respectively.No obvious apoptosis was observed in the treated cells.Anti-metastatic activities were shown on HCT8 cells by inhibiting the migration and invasion.Meanwhile,the expression of MMP2,MMP9,and phosphorylated Integrinb1 were decreased.Digoxin inhibited the proliferation,migration,and tube formation of HUVECs and reduced HIF1a expression and vascular endothelial growth factor A(VEGF-A)secretion in HCT8 cells,suggesting anti-angiogenic activity.Furthermore,digoxin significantly reversed ABCB1-mediated multidrug resistance on SW620/Ad300 cells.Conclusion Our findings suggest that digoxin has the potential to be applied as an antitumor drug via inhibiting proliferation and metastasis as well as reversing the ABCB1-mediated multidrug resistance of colorectal cancer.展开更多
基金supported by the Science&Technology Development Fund of Tianjin Education Commission for Higher Education[2017KJ230].
文摘Background Colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.Novel drugs for CRC therapy are urgently needed.Digoxin has been in clinical use for treatment of heart failure and atrial arrhythmias for many years.Fragmentary reports suggested that digoxin might have antitumor efficacy on CRC.Here,we aimed to investigate the antitumor effect of digoxin on human CRC cells and the underlying mechanism.Methods Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay and plate colony formation assay.The effects of digoxin on cell-cycle distribution and apoptosis were analysed by flow cytometry.The anti-metastatic effect on tumor cells was determined by wound-healing assay and transwell assay.Anti-angiogenic effect was examined by determining the inhibition against proliferation,migration,and tube formation of human umbilical vein endothelial cells(HUVECs).Mechanism study was performed by Western blot,enzyme-linked immunosorbent assay(ELISA),and gelatin-zymography assay.Results Digoxin potently inhibited cell proliferation,induced G1-phase and G2/M-phase arrest in colorectal-cancer HCT8 and SW620 cells,respectively.No obvious apoptosis was observed in the treated cells.Anti-metastatic activities were shown on HCT8 cells by inhibiting the migration and invasion.Meanwhile,the expression of MMP2,MMP9,and phosphorylated Integrinb1 were decreased.Digoxin inhibited the proliferation,migration,and tube formation of HUVECs and reduced HIF1a expression and vascular endothelial growth factor A(VEGF-A)secretion in HCT8 cells,suggesting anti-angiogenic activity.Furthermore,digoxin significantly reversed ABCB1-mediated multidrug resistance on SW620/Ad300 cells.Conclusion Our findings suggest that digoxin has the potential to be applied as an antitumor drug via inhibiting proliferation and metastasis as well as reversing the ABCB1-mediated multidrug resistance of colorectal cancer.
